SUMMARY Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double blind crossover protocol, each treatment period lasting six weeks. Resting intra-arterial pressure in the recumbent position was reduced from 150/84 to 141/77 mm Hg; the hypotensive effect persisted throughout an uninterrupted graded exercise test to the point of exhaustion. The haemodynamic effects were similar at rest and during exercise. Overall, systemic vascular resistance decreased by 14%, heart rate fell by 5%, but stroke volume and cardiac output increased. Mean pulmonary arterial pressure and capillary wedge pressure were not significantly affected, but pulmonary vascular resistance decreased by 15%.
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The pressor response to methoxamine was significantly reduced by ketanserin. Both plasma noradrenaline and adrenaline concentrations increased, plasma renin activity and angiotensin II concentration decreased, and plasma aldosterone concentration was unchanged.
The data indicate that ketanserin induces arteriolar dilatation, possibly related to an alpha-lantagonistic action and to a reduced circulating angiotensin II concentration. The haemodynamic response is complex, and an increase in cardiac output limits the hypotensive effect. There is no firm evidence of an effect on venous tone as cardiac filling pressures do not change.
Ketanserin is a new drug which may be of value for treating a variety of cardiovascular diseases.' Benefits have been reported in hypertension,2" heart failure,5
Raynaud's phenomenon,6 and thrombophlebitis.7 The drug has high binding affinity for 5-hydroxytryptamine type 2 receptors8 and it inhibits the 5-hydroxytryptamine induced vasoconstriction of isolated arterial and venous strips of rats and dogs.9 Alpha-i-receptor blocking properties have also been found in the rat."'-'2 Some acute mechanisms of action of ketanserin have been studied in man. The drug inhibits platelet aggregation induced by 5-hydroxytryptamine,"' and does not affect the pressor effect of phenylephrine in sodium depleted normotensive subjects '4 Accepted for publication 26 July 1983 ing to an alpha-1-antiadrenergic activity."6 Blood pressure is considerably reduced in hypertensive patients2 4 and in normotensive subjects during exercise,'7 owing to a reduction in systemic vascular resistance.4 '7 Chronic administration of ketanserin lowers blood pressure in hypertension,3 but the mechanisms have not been studied. To clarify haemodynamic and humoral mechanisms we studied patients with mild to moderate essential hypertension in a randomised placebo controlled double blind crossover trial.
Patients and methods
Fourteen patients with essential hypertension were studied, and their characteristics are given in Table 1 which the patients received placebo, ketanserin (three 40 mg capsules per day) and placebo (three identical capsules a day) were given for six weeks each, according to a randomised crossover double blind protocol. At the end of each period patients underwent haemodynamic investigation in the morning, after the patient had had a light breakfast at home, in a laboratory where the room temperature was 18-22°C and humidity 40-60%. The patients took the morning capsule on arrival in the laboratory at about 8.30 am. Two patients refused the haemodynamic investigation at the second visit. In the remaining 12 patients the brachial artery was punctured (Vygon, 115 09) twice to measure systolic, diastolic, and mean intra-arterial pressures and to sample arterial blood. In eight patients, of whom five received treatment first and three received placebo first, a venous catheter (SwanGanz, 93-110 5F) was introduced on both occasions into the antecubital vein and positioned in the pulmonary artery to After stopping the drug infusion, 45-60 minutes was allowed for its effect to dissipate. All patients were seated on the bicycle ergometer and the resting measurements were obtained 10 minutes later. A graded, uninterrupted exercise test was then started at a work load of 10 W for 1 minute, and the load was increased by 10 W every minute until the patients were exhausted. At one third and two thirds of predetermined maximal work load (determined during the run in period) the work load was maintained for 4 minutes to allow steady state haemodynamic measurements and blood samples to be obtained. Biochemical tests were performed on arterial blood. Plasma renin activity was determined by the method of Fyhrquist and Puutula'8; plasma angiotensin II and plasma aldosterone concentration as described by Lijnen et al, 19 20 and plasma lactate concentration by an enzymatic method.2' Plasma noradrenaline and plasma adrenaline concentrations were measured according to the method ofda Prada et al. 22 Plasma concentrations of ketanserin were determined by Janssen Pharmaceutica using high piesspre liquid chromatography (method to be published).
STATISTICAL ANALYSIS
Treatment with ketanserin and placebo are compared using either paired t tests or three way analysis of variance with treatment, subjects, and levels of activity (or the infusion rate of the alpha agonist) and their interactions considered as sources of variance. For the latter analysis only the effects of treatment and the interactions between treatment and level of physical activity (or infusion rate of the alpha agonist) are used; the significance of the difference between ketanserin and placebo data at a given level of activity or at a given infusion rate was assessed using the residual mean square from the analysis of variance. (The F value refers to the effect of treatment and Fi to the interaction between treatment and levels of activity.)
For plasma renin activity and plasma angiotensin II, aldosterone, noradrenaline, and adrenaline concentrations, the statistical analysis was performed on the log values since their distribution was closer to Gaussian; the geometric mean and range are therefore given. Other values are given as mean ± SE.
Results

EFFECT OF KETANSERIN ON MAXIMUM EXERCISE CAPACITY
During treatment with ketanserin the mean total exercise time was 1423±84 s, which was not signifi-cantly different from the value obtained during treatment with placebo (1429±96 s). The highest oxygen uptake was 2-18±0 16 1/min with placebo and 2 21 ±0@19 with ketanserin, and the difference was not significant (NS). At the final work load during placebo treatment the mean values (± SD) of respiratory gas exchange ratio, respiratory equivalent for oxygen, and arterial pH were 1 03±0 02, 33-8±1-4, and 7-32±0-02 respectively; the values during treatment with ketanserin (1 04±0i02, 32-8±F16, and 7-31±0i02 respectively) were not significantly different. Plasma lactate concentration was measured 1, 3, and 5 min after stopping exercise; the mean of the highest of the three values obtained was 7T9±O 9 mmol/l (71±8 mg/ 100 ml) during treatment with placebo and 8-8± 12 mmol/l (79±11 mg/100 ml) during ketanserin treatment (NS).
EFFECT OF KETANSERIN ON SYSTEMIC HAEMODYNAMICS
The overall analysis of resting and exercise data, using three way analysis of variance is presented in Fig. 1-3 . For comparison with other studies which report only resting data we have given resting data separately (Table 2 ). (e/*) of peak work rate Fig. 1 Systolic, diastolic, and mean intra-arterial pressures at rest in the recumbent position (RR), at rest sitting (RS), and at various levels ofexercise, expressed as a percentage ofpeak work rate, during placebo and during ketanserin treatment. The F value refers to the effect of treatment; there were no significant interactions between the effect oftreatment and the levels of physical activity (n= 12).
Data at rest
Overall data Ketanserin reduced overall systolic, mean, and diastolic intra-arterial pressures (F=53, p<OOOl; F= 189, p<0001; and F=234, p<0001 respectively).
( Fig. 1 ). There were no significant interactions between the effect of treatment and the level of activity (Fi -1 -0; NS Ketanserin reduced systemic vascular resistance (F=20; p<0001), increased cardiac output (F=13; p<001) and stroke volume (F=21; p <01001), but reduced heart rate (F=30; p<0001) ( Fig. 2 and 3 ). There were no significant interactions between the effect of treatment and the level of activity (Fi <2-4; NS). The mean overall changes were a 14% decrease in systemic vascular resistance, a 7% increase in cardiac output, an 11% increase in stroke volume, and a 5% decrease in heart rate. The change in cardiac output was based on a decreased difference in arteriovenous oxygen content (F=40; p<001) with unchanged oxygen uptake (F= 1 4; not significant).
Effect ofketanserin on pressures in the right heart and on pulmonary haemodynamics The Table 3 summarises the overall data for mean pulmonary artery pressure and mean pulmonary capillary wedge pressure, which were not significantly affected by ketanserin (F <1 -0). Pulmonary vascular resistance was reduced (F=75; p<0 1).
Effect ofketanserin on the pressor response to alpha receptor stimulation Fig. 4 shows that the effect of the alpha receptor agonist methoxamine on systolic intra-arterial pressure during ketanserin treatment was reduced compared with placebo (F=9-7; p<0 01). Also the interaction between the effect of ketanserin and the infusion rates of methoxamine (Fi= 10-2; p<0 01) was significant.
The increase in systolic intra-arterial pressure with methoxamine was significantly reduced during ketanserin treatment at the highest rate of infusion.
Methoxamine, 800 gg/min, increased systolic intraarterial pressure by 33 mm Hg during placebo and by 22 mm Hg during ketanserin (p<0 01).
Effect ofketanserin on the renin angiotensin aldosterone system and on plasma catecholamine concentrations Plasma renin activity was reduced by ketanserin (F=37; p<0 001) without interaction with the level of physical activity (Fi=0-6; NS). Also (Fig.6 ).
Other effects ofketanserin Ketanserin increased mean body weight from 74X3±3-6 to 75 3±-3±6 kg (p<0-05).
During treatment with placebo mean haemoglobin concentration was 14-4±0-4 g/dl at rest in the recumbent position, 15-1±0'5 g/dl at rest sitting, and 15-3±0-5, 15-5±0-5 and 15-5±0-5 g/dl at 33%, 66%, and 100% of the maximum work rate respectively. The concentrations during treatment with ketanserin Levels of physical activity (%) Fig. 5 Plasma renin activity, plasma angiotensin II concentration, and plasma aldosterone concentration at rest in the recumbent position, at rest sitting (RS), and at 66% and 100% ofpeak work rate during placebo and during ketanserin treatment. The F value refers to the effect oftreatment; there were no significant interactions between the effect oftreatment and the levels ofphysical activity (n= 12). Values are means±SE. 6 Plasma noradrenaline and adrenaline concentrations at rest in the recumbent position (RR), at rest sitting (RS), and at 66% and 100% ofpeak work rate, during placebo and during ketanserin treatment. The F value refers to the effect of treatment; there were no significant interactions between the effect oftreatment and the levels ofphysical activity (n= 10). Values are means±SE. during chronic oral treatment ofhypertensive patients. This is compatible with alpha-l-antagonist activity. We cannot establish, however, if the antagonistic activity is competitive or non-competitive. Indeed, because of limitations in the pressor rise that can be induced with alpha agonists in humans, full log dose response curves cannot be constructed. Therefore, we cannot find out whether or not a parallel shift of the curve occurs during ketanserin treatment. Various non-specific mechanisms could have interfered such as inhibition of the amplification of alpha receptor agonism by serotonin,' differences in background plasma angiotensin II and plasma noradrenaline concentrations, a lower blood pressure before the alpha agonist test during ketanserin treatment, or a possible reduction of vascular hypertrophy after six weeks of ketanserin treatment. Furthermore, in contrast to observations after acute administration, ' 
